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Abstract
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new treatment that applies
chemotherapeutic drugs into the peritoneal cavity as an aerosol under pressure. It improves local bioavailability of
chemotherapeutic drugs as compared with conventional intraperitoneal chemotherapy. It has been proved to be safe
and feasible if performed as an exclusive treatment in patients affected by peritoneal carcinomatosis. The first results
in patients treated with PIPAC associated with systemic chemotherapy are presented.
Methods: Between June 2015 and February 2016, 57 PIPAC applications with oxaliplatin or cisplatin + doxorubicin
every 6 weeks at 37 °C and 12 mmHg for 30 min were performed. Forty PIPAC procedures performed in 14 patients
were included in this study; thirteen patients were undergoing systemic chemotherapy with a wash-out interval of at
least 2 weeks before and 1 week after each PIPAC. Safety, tolerability, and postoperative complications were assessed
by collection of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) 2.
Results: Forty PIPAC administrations were performed in 14 patients with no major perioperative complications. CTCAE
grades 1 and 2 were observed after six and eight procedures, respectively, for abdominal pain and nausea. Renal and
hepatic functions were not impaired; no cumulative renal toxicity was observed after repeated PIPAC procedures in
association with systemic chemotherapy.
Conclusions: These preliminary data show that the association of PIPAC and systemic chemotherapy does not induce
significant hepatic and renal toxicity. It allows inclusion of patients with extraperitoneal disease or at a high risk of
developing it. Further studies are needed to assess whether this combination therapy could become part of the
standard treatment for peritoneal carcinomatosis.
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Background
For a long time, peritoneal carcinomatosis (PC) has been
regarded as a terminal disease. Traditional treatment con-
sists of systemic chemotherapy, with or without palliative
surgery, resulting in poor effects in terms of outcome. With
the development of more effective chemotherapeutic drugs
and target therapies, expected median survival rose to
20 months for colorectal cancer (CRC) [1], 4–10 months
for epithelial ovarian cancer (EOC) [2], 7–10 months for
gastric cancer (GC) [3], and 6–12 months for peritoneal
mesothelioma (DMPM) [4]. Sugarbaker et al. challenged
this oncologic philosophy and suggested that PC, in the
absence of distant metastases, should be considered as a lo-
cally advanced disease for which an aggressive approach
can be justified [5]. For these reasons, a multimodal treat-
ment based on cytoreductive surgery (CRS) and hyperther-
mic intraperitoneal chemotherapy (HIPEC) in association
with systemic therapy was developed.
Unfortunately, only selected patients may undergo this
combined procedure, and anyway, its role in the treatment
of some pathologies such as gastric cancer remains a mat-
ter of considerable debate [6]. Moreover, this treatment is
still hampered by significant risks and side effects with a
30-day mortality rate of 5 % in referral centers [7].
A further aspect of intraperitoneal chemotherapy is the
pharmacological limitation in terms of poor drug distribu-
tion in the peritoneal cavity and penetration into peritoneal
nodules. Pressurized intraperitoneal aerosol chemotherapy
is an innovative intraperitoneal chemotherapy (IPC) con-
cept that seems to enhance the effectivity of IPC by taking
advantage of the physical properties of gas and pressure [8].
Preliminary experiences reported in literature are based
on strict exclusion criteria: patients with extra abdom-
inal metastatic disease including retroperitoneal dis-
ease, patients who underwent chemotherapy or surgery
within the last 4 weeks, or patients who undergo any
cancer-specific treatment during the study cannot be
included [9–12]. The narrowness of the selection criteria
may exclude many patients that, presenting an advanced
stage of the disease, often show extra-abdominal lesions
or simply aortic/para-aortic lymph node recurrence.
PIPAC procedure is resulted to be safe, with no post-
operative renal and hepatic toxicity [13–15]; in this
paper, we would prove, through our preliminary results,
the safety and feasibility of PIPAC associated with sys-
temic chemotherapy in order to expand the cohort of
patients who can most benefit from this treatment.
Methods
Between June 2015 and February 2016, 57 PIPAC proce-
dures were carried out in 29 patients with PC (seven CRC,
five EOC, four DMPM, two appendiceal cancers, nine GC,
two breast cancers); we considered for this study 40 appli-
cations performed in 14 patients (two CRC, three EOC,
two DMPM, one appendiceal cancer, six GC); some of
them were treated within the framework of off-label
use applications, awaiting for Italian Drug Agency
(AIFA—Agenzia Italiana del Farmaco) approval of an
open-label, single-arm, phase II clinical trial [https://clini
caltrials.gov/ct2/show/NCT02604784]. Patients aged be-
tween 18 and 78 years, presenting a good performance
status (ECOG ≤ 2) with clinical and pathological confirm-
ation of peritoneal carcinomatosis from gastric, colorectal
and ovarian cancers, or primary peritoneal tumors were
included. Patients were required to have undergone at
least one line of previous i.v. standard chemotherapy in
DMPM and two lines in CRC and EOC. Patients, contrary
to other trials, were not required to stop any other cancer-
specific treatment during our study.
Specifically, we included patients undergoing systemic
chemotherapy but had stopped it during 2 weeks before
and 1 week after PIPAC procedure. All patients signed
an informed consent. Lastly, patients were eligible if they
had blood and electrolyte counts, liver, renal, and cardio-
pulmonary function parameters within 10 % of the nor-
mal range; tumor mass present on CT-scan in order to
allow tumor response assessment with RECIST-criteria.
Finally, any of the following was regarded as a criterion
for exclusion from the study: bowel obstruction, severe
renal impairment, myelosuppression, severe hepatic im-
pairment, severe myocardial insufficiency, recent myocar-
dial infarction, severe arrhythmias, immuno-deficiency
such as patients with an immunosuppressive medication
or a known immune system disease, creatinine clearance
<60 ml /min, pregnancy, previous treatment reaching the
maximum cumulative dose of doxorubicin, daunorubicin,
epirubicin, idarubicin, and/or other anthracyclines and
anthracenediones, known allergy to cisplatin or other
platinum-containing compounds or to doxorubicin, re-
fusal to conduct complete abstinence from heterosexual
relationships or agree to use an effective clinically accept-
able method (with failure rate <1 %) during the study and
the following 6 months after the last treatment.
All operations were performed under general anesthesia;
venous thromboembolism prophylaxis was administered
the night before surgery using low molecular weight hep-
arin (LMWHs), and antibiotic prophylaxis with a single
dose of Cefazolin 2 g IV was administered 30 min before
surgery.
An open access with a midline 5–6-cm incision was per-
formed and a single-port platform (Quad-Port Olympus)
was positioned according to our original technique. A
12 mmHg CO2 pneumoperitoneum was inflated. Ascites
were removed if present and the amount documented. PC
extent was evaluated according to the Sugarbaker Periton-
eal Cancer Index (PCI) [16], and multiple peritoneal biop-
sies were taken. A nebulizer (MIP, Reger Medizintechnik,
Rottweil, Germany) was connected to an high-pressure
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injector and inserted into the peritoneal cavity; the tightness
of the abdomen was documented with a CO2 zero-flow.
The camera and the nebulizer are maintained in position
by a self-retaining retractor (Thompson). A pressurized
aerosol containing cisplatin 7.5 mg/m2 body surface in
150 ml NaCl 0.9 % + doxorubicin 1.5 mg/m2 body surface
in 50 ml NaCl 0.9 % in patients with EOC and DMPM
and oxaliplatin 92 mg/m2 body surface in 150 ml dextrose
solution in patients with CRC was applied through the
nebulizer. Injection parameters were flow of 30 ml/min
and a max upstream pressure of 200 psi with an intra-
abdominal pressure of 12 mmHg [10–12]. The injection
was remote-controlled in order to avoid occupational ex-
posure. The capnoperitoneum was then maintained for
30 min at 37 °C. At the end, the aerosol was exsufflated
through two sequential micro-particle filters into the air-
waste system of the hospital. Single-port platform was re-
moved; no abdominal drain tube was applied. Nasogastric
tube and urinary catheter were removed at the end of the
operation.
Peripheral venous blood was collected preoperatively,
the day of the intervention and daily until the discharge.
Creatinine and urea clearances measurement was per-
formed before each operation.
Data of all patients who underwent PIPAC procedure
were included in a prospectively maintained database.
Safety, tolerability, and postoperative complications were
assessed by collection of adverse events, according to
the Common Terminology Criteria for Adverse Events
(CTCAE) 2 including physical examination results and
laboratory assessments (chemistry and hematology).
Statistics was performed using SPSS version 22 software.
Comparative statistics over time was performed by one-way
repeated analysis of quantitative variables (t student test).
Results
Between June 2015 and February 2016, 40 PIPAC proce-
dures were performed in five patients (one DMPM, one
EOC, one CRC, one appendiceal cancer, one GC); in 13
patients, PIPAC was performed in association with sys-
temic chemotherapy with a wash-out interval of at least
2 weeks before and 1 week after each procedure. Patient
characteristics including the kind of systemic chemo-
therapy performed are shown in Table 1.
We reported a mean operative time of 86 min (range
45–145), a laparoscopic access rate of 100 % with no post-
operative re-laparotomies. The mean hospital stay was
3 days. Mean PCI was 17 (range 12–21). CTCAE grades 1
and 2 were observed in six and eight patients, respectively.
Six out of 13 patients presented mild abdominal pain and
eight patients complained of nausea. None presented fever.
No postoperative mortality was reported. Patient 1 re-
ceived only two PIPAC procedures because of the inability
to create a good laparoscopic chamber due to adhesion
increase.
A slight leukocytosis was recorded after most of the
procedures, often associated with an increase in C-
reactive protein (CRP) because of the chemical peri-
tonitis due to the chemotherapy agents with a peak on
the second postoperative day (POD) (mean 0.048 ±
0.036, p = 0.002) followed by a decrease on POD 3.
Table 1 Patient Characteristics
Age Disease First diagnosis Previous surgery Previous sCT Associated sCT PIPAC
procedure
Pat 1 62 DMPM April 2012 2 CRS + HIPEC 1 line – 2
Pat 2 71 EOC September 2010 ARR, ovarectomy, hysterectomy,
omentectomy, lymphadenectomy
7 lines Topotecan (days 1, 8, 15) 3
Pat 3 68 CRC May 2014 Explorative laparotomy 2 lines Folfox + Cetuximab 4
Pat 4 43 PMP August 2013 Debulking 2 lines + irinotecan IP Folfoxiri 4
Pat 5 61 EOC September 2012 ARR, small bowel resection, ovarectomy,
hysterectomy, omentectomy
3 lines Weekly paclitaxel 3
Pat 6 39 GC December 2014 Explorative laparotomy 2 lines Folfiri 3
Pat 7 51 GC November 2013 Gastric resection 2 lines Paclitaxel + ramucirumab 3
Pat 8 47 GC July 2015 Explorative laparoscopy 1 line Xelox 3
Pat 9 53 EOC September 2014 Ovarectomy, hysterectomy, 2 lines Paclitaxel 2
Pat 10 78 DMPM April 2015 Explorative laparoscopy 1 line Pemetrexed 3
Pat 11 51 CRC August 2011 CRS + HIPEC 2 lines Cetuximab 2
Pat 12 55 GC January 2015 Gastric resection, omentectomy, 1 line CDDP + teysuno 2
Pat 13 45 GC December 2013 Gastric resection 1 line CDDP + gemcitabine 3
Pat 14 52 GC July 2015 1 line Paclitaxel + ramucirumab 3
sCT systemic chemotherapy, CRS cytoreductive surgery, ARR anterior rectal resection, IP intraperitoneal, DMPM diffuse malignant peritoneal mesothelioma, EOC
epithelial ovarian cancer, CRC colorectal cancer, PMP pseudomyxoma peritonei, and GC gastric cancer
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No signs of liver toxicity were observed after the pro-
cedures, and all indices of liver function remained in the
normal range; we reported a minimum increase of ASAT
on POD 0 (mean 24 ± 15.3, p = 0.21); ALAT and serum
gamma-GT remain stable during the whole hospital stay.
Analogously, serum amylase values were stable, with a
peak on POD 3 (mean 193.5 ± 145.5), not significantly
higher than the preoperative value (mean 193.0 ± 66.6).
Total bilirubin serum levels reported a slight increase on
POD 1 (mean 0.8 ± 0.6) without any clinical relevance.
Renal function was not impaired; preoperative serum
creatinine and creatinine/urea clearances were in range
and did not increase; preoperatively mean serum cre-
atinine value was 0.8 ± 0.2 and it remained stable during
the whole hospital stay. No cumulative renal toxicity was
observed after repeated PIPAC procedure at 6-week
Fig. 1 Box plot of liver, renal, and pancreatic functions before the intervention and during the hospital stay. The light blue and blue boxes
represent the second and the third quartile, respectively. The upper and lower whiskers represent scores outside the middle 50 %, the highest and
lowest value, respectively. The red line represents the upper limit of normal range of measured parameters. PIPAC pressurized intraperitoneal
aerosol chemotherapy, CTCAE common terminology criteria for adverse events, PC peritoneal carcinomatosis, CRC colorectal cancer, EOC epithelial
ovarian cancer, GC gastric cancer, DMPM diffuse malignant peritoneal mesothelioma, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal
chemotherapy, IPC intraperitoneal chemotherapy, CT computed tomography, LMWH low molecular weight heparin, PCI Peritoneal Cancer Index,
CRP C-reactive protein, POD postoperative day, and QoL quality of life
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intervals in association with systemic and intraperitoneal
chemotherapy. The details about liver and renal toxicity
laboratory data are reported in Fig. 1.
At discharge, each patient presented good general condi-
tions, blood tests were in range, and regularly underwent
the planned systemic chemotherapy without cumulative
toxicity.
Quality of life (QoL) was recorded routinely in all pa-
tients before the enrollment and after each PIPAC pro-
cedure through two questionnaires: SF-36 and EORTC
QLQ-30. No further deterioration of physical, emotional,
and cognitive scores during therapy were recorded.
Discussion
These preliminary data about patients treated with
PIPAC in association with systemic chemotherapy show
that the combined treatment does not induce significant
hepatic and renal toxicity.
PIPAC pharmacokinetics permit to use a minimal drug
dose reaching a higher intraperitoneal concentration than
in HIPEC; in fact, intra-abdominal pressure increases tis-
sue uptake, intra-tumoral drug concentration [17, 18], and
the micronization of the cytostatic agent creates a thin film
of microdroplets over the entire peritoneal cavity, increas-
ing the contact surface area between drugs and tissues. In
fact, the micro-injection pump creates micron-size drug
particles reducing the average diameter of a chemothera-
peutic infusion.
On the basis of these features, PIPAC resulted to be a
well-tolerated treatment without major postoperative com-
plications. Liver and renal tests showed neither acute nor
cumulative toxicity after the procedures. Objective, radio-
logical, and serological disease regression was observed in
five patients; stable disease was recorded in two patients.
In seven patients, we reported a disease progression at a
later stage. The aim of this paper is to prove the safety and
feasibility of PIPAC associated with systemic chemother-
apy; this demonstration, in fact, may allow treatment of pa-
tients who, presenting an advanced stage of disease, may
have ascites and complain of sub-occlusive symptoms and
abdominal pain due to peritoneal disease. The comple-
mentary systemic treatment permits to include patients
who, for cancer clinical stage, may present retroperiton-
eal adenopathy, parenchymal metastases, or even extra-
abdominal disease, for which PIPAC is not effective,
expanding the population of patients who can most
benefit from this treatment.
In patients presenting a good general condition but a
worsening quality of life because of peritoneal disease
diffusion, the combination of the two treatments enables
rapid symptom palliation with PIPAC and a risk reduc-
tion of extra-abdominal metastasis thanks to systemic
chemotherapy.
The progression disease reported in five patients
probably means that the PIPAC procedure has yet to be
improved. Probably, PIPAC may enhance the activity of
systemic chemotherapy (for example, by reducing the
intra-tumoral interstitial fluid pressure), but as PIPAC
alone, on the basis of our preliminary experience with
the current drugs doses, it is not sufficiently effective.
A dose-finding study for the determination of the opti-
mal dose is mandatory.
In this perspective, PIPAC may not only be considered a
palliative treatment, but in combination with systemic
chemotherapy, with appropriate drug doses, it could pos-
sibly become part of the standard therapeutic course of
peritoneal carcinomatosis, as it has been shown for IPC
(intraperitoneal chemotherapy) [19, 20] and HIPEC for
certain diseases [21–34].
Conclusions
This preliminary analysis demonstrates that the com-
bined treatment based on PIPAC and systemic chemo-
therapy does not induce significant hepatic and renal
toxicity.
Certain tumors in advanced stage of disease, may present
not only PC but also lymph node or retroperitoneal metas-
tasis. In those cases, PIPAC would be ineffective, but con-
sidering its low toxicity and postoperative morbidity, may
be associated with systemic chemotherapy. This combined
treatment as well as being ethically accepted, may be a use-
ful strategy for patients presenting extraperitoneal disease
or at a high risk of developing it.
These preliminary results obtained in a small cohort of
patients provide a rational for prospective studies in
order to improve the technique and assess whether this
combination therapy could become part of the standard
treatment for peritoneal carcinomatosis.
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